Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Cell Dev. Biol.

Sec. Molecular and Cellular Pathology

Proteolytic Enzyme Models as Tunable Preclinical Platforms for Investigating Intervertebral Disc Degeneration

Provisionally accepted
Jan  GewiessJan Gewiess1Annamarie  D’IntinoAnnamarie D’Intino2Alejandra  SantosAlejandra Santos2Mauro  AliniMauro Alini3Andrea  VernengoAndrea Vernengo2*
  • 1Universitat Bern, Bern, Switzerland
  • 2Rowan University, Glassboro, United States
  • 3AO Research Institute Davos, Davos, Switzerland

The final, formatted version of the article will be published soon.

Lower back pain (LBP) caused by intervertebral disc (IVD) degeneration is a major global health burden, with significant socioeconomic costs. This review examines proteolytic enzyme-based models for inducing IVD degeneration, focusing on their advantages over mechanical and puncture methods, which often fail to replicate the chronic, multifactorial nature of human degeneration. Enzymatic models, such as chemonucleolysis using chondroitinase ABC (ChABC), chymopapain, collagenase, papain, and trypsin, selectively degrade extracellular matrix components like aggrecan and collagen, mimicking the biochemical and structural changes seen in human IVD degeneration. These models offer controlled, reproducible, and physiologically relevant platforms for studying disease progression and evaluating regenerative therapies. Key findings include the dose-and time-dependent effects of enzymes on disc height loss, biomechanical properties, and matrix composition, as well as their ability to induce mild to moderate degeneration without acute trauma. Comparative studies highlight ChABC's suitability for early-stage degeneration, while chymopapain and papain produce more severe changes. Enzyme models also provide insights into cellular responses, such as cytokine upregulation and matrix remodeling, which are critical for developing targeted treatments. By enabling precise modulation of degenerative severity, these models hold promise for advancing preclinical research and optimizing regenerative strategies for IVD repair. Looking forward, integrating behavioral and molecular pain outcomes into enzyme-based systems may further enhance their translational value, allowing future models to capture both structural and symptomatic dimensions of disc disease.

Keywords: ChABC, Chemonucleolysis, Chondroitinase ABC, Chymopapain, collagenase, Intervertebral Disc Degeneration, Papain, Trypsin

Received: 20 Aug 2025; Accepted: 27 Nov 2025.

Copyright: © 2025 Gewiess, D’Intino, Santos, Alini and Vernengo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Andrea Vernengo

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.